Repare Therapeutics Inc. (RPTX): Price and Financial Metrics


Repare Therapeutics Inc. (RPTX): $33.43

-0.45 (-1.33%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

RPTX POWR Grades


  • Growth is the dimension where RPTX ranks best; there it ranks ahead of 72.14% of US stocks.
  • The strongest trend for RPTX is in Momentum, which has been heading down over the past 31 weeks.
  • RPTX ranks lowest in Momentum; there it ranks in the 9th percentile.

RPTX Stock Summary

  • RPTX's went public 0.97 years ago, making it older than only 0.6% of listed US stocks we're tracking.
  • With a price/sales ratio of 3,818.08, Repare Therapeutics Inc has a higher such ratio than 99.52% of stocks in our set.
  • With a year-over-year growth in debt of 330.2%, Repare Therapeutics Inc's debt growth rate surpasses 96.42% of about US stocks.
  • Stocks that are quantitatively similar to RPTX, based on their financial statements, market capitalization, and price volatility, are VNRX, TRCH, AQB, VHC, and HUSN.
  • To dig deeper into the stock's financial statements, go to RPTX's page on browse-edgar?action=getcompany&CIK=0001808158.

RPTX Price Target

For more insight on analysts targets of RPTX, see our RPTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $46.50 Average Broker Recommendation 1.57 (Moderate Buy)

RPTX Stock Price Chart Interactive Chart >

Price chart for RPTX

RPTX Price/Volume Stats

Current price $33.43 52-week high $46.44
Prev. close $33.88 52-week low $21.45
Day low $32.85 Volume 90,500
Day high $33.98 Avg. volume 145,084
50-day MA $32.65 Dividend yield N/A
200-day MA $31.78 Market Cap 1.24B

Repare Therapeutics Inc. (RPTX) Company Bio


Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company was founded by Daniel Durocher, Agnel Sfeir and Frank Sicheri on September 6, 2016 and is headquartered in Saint-Laurent, Canada.


RPTX Latest News Stream


Event/Time News Detail
Loading, please wait...

RPTX Latest Social Stream


Loading social stream, please wait...

View Full RPTX Social Stream

Latest RPTX News From Around the Web

Below are the latest news stories about Repare Therapeutics Inc that investors may wish to consider to help them evaluate RPTX as an investment opportunity.

2 Biotech Stocks ARK Invest Bought in June

Over the past few years, Cathie Wood's ARK Invest group of exchange-traded funds have delivered impressive gains. ARK Invest's most successful fund over the past year, the ARK Genomic Revolution ETF (NYSEMKT: ARKG) has the best performer of the bunch with an incredible 80% gain over the past 12 months. On Jun. 3, 2021, the ARK Genomic Revolution ETF bought shares of these two clinical-stage biotechs.

Yahoo | June 7, 2021

Repare Therapeutics to Participate at the 42nd Annual Goldman Sachs Virtual Global Healthcare Conference

Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq:RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that members of its senior management team will participate in a fireside chat at the 42nd Annual Goldman Sachs Virtual Global Healthcare Conference on Wednesday, June 9 at 3:50 p.m. Eastern Time.

Yahoo | June 2, 2021

Here's Why We're Not At All Concerned With Repare Therapeutics' (NASDAQ:RPTX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | May 11, 2021

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306, a First-in-Class, Selective, Oral Inhibitor of PKMYT1

Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality (SL) approach to the discovery and development of novel therapeutics, today announced the first patient has been dosed in the Company’s Phase 1 clinical trial of RP-6306, a first-in-class small molecule product candidate targeting PKMYT1, which is a novel target that Repare discovered to be synthetic lethal with CCNE1 amplification and other genomic mutations to treat CCNE1-amplified, FBXW7-altered and other PKMYT1 inhibitor-sensitive cancers.

Yahoo | May 3, 2021

Repare Therapeutics to Highlight Program Progress for RP-6306 at Today’s Virtual Investor Day Event

Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, will host a virtual Investor Day webcast today from 10:30 a.m. – 12:00 p.m. ET, highlighting the progress of its proprietary RP-6306 program for tumors with genetic alterations characterized by CCNE1 amplification. The Company expects to initiate a Phase 1 clinical trial of RP-6306 in the second quarter of 2021.

Yahoo | April 8, 2021

Read More 'RPTX' Stories Here

RPTX Price Returns

1-mo 3.24%
3-mo 17.88%
6-mo -10.28%
1-year N/A
3-year N/A
5-year N/A
YTD -2.54%
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.997 seconds.